HIGHLIGHTS
- who: Sandra Roche et al. from the National Institute for Cellular Biotechnology, City University, Glasnevin, have published the research: Preclinical evaluation of Insulin-like growth factor receptor 1 (IGF1R) and Insulin Receptor (IR) as a therapeutic targets in triple negative breast cancer, in the Journal: PLOS ONE of 26/07/2022
- what: The authors aimed to test if inhibiting both IR/IGF1R was a rationale therapeutic approach to treat TNBC. The authors aimed to determine if xentuzumab could enhance response to treatment with either chemotherapy or PI3K inhibition in the CAL-51 and HCC1143 cell . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.